Auris Medical and King's College London Extend Tinnitus Collaboration
Wednesday, February 22, 2017 8:00:46 AM ET
- Selection of lead compound for AM-102 program planned for 2017
Auris Medical Holding AG (EARS ), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the extension of its collaboration with Kings College London. The collaboration is focused on the discovery of small molecule compounds for a second generation tinnitus treatment.
"Together with Kings College London, we have made great progress on our second generation tinnitus project," commented Thomas Jung, MD, PhD, Auris Medicals Chief Development Officer. "The teams drug discovery expertise has generated interesting leads that have been tested in vitro and in vivo. The extension of our collaboration allows for further development with the aim of selecting a lead compound for our AM-102 program by the end of 2017."
Professor David E. Thurston of the Institute of Pharmaceutical Science is leading the team at Kings to develop and optimize a range of specific small molecules for Auris Medicals AM-102 project. The project builds on earlier work performed at Kings for Auris Medical by Professor Pat Doherty and Dr. Gareth Williams. The AM-102 compounds bind to a novel, undisclosed drug target for treating certain types of tinnitus.
<b>About Inner Ear Tinnitus</b>
Tinnitus is the perception of sound without external acoustic stimulation. Tinnitus of the inner ear may be caused by various injuries to the cochlea, the organ of hearing, such as overexposure to noise. Tinnitus that has been present for less than three months is considered acute, while tinnitus that has been present for over three months is considered chronic. Tinnitus of the inner ear often has a serious impact on ability to sleep, relax or concentrate, which may lead to tiredness, irritation, anxiety or depression. There is no universal standard of care for tinnitus of the inner ear and efficacy of a pharmacological treatment for tinnitus of the inner ear has not yet been conclusively demonstrated.
<b>About Auris Medical</b>
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing intranasal betahistine for Menieres disease and vestibular vertigo (AM-125) and early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
<b>About Kings College London</b>
Kings College London is one of the top 25 universities in the world (2016/17 QS World University Rankings) and among the oldest in England. Kings has more than 27,600 students (of whom nearly 10,500 are graduate students) from some 150 countries worldwide, and some 6,800 staff.
Kings has an outstanding reputation for world-class teaching and cutting-edge research. In the 2014 Research Excellence Framework (REF) Kings was ranked 6th nationally in the power ranking, which takes into account both the quality and quantity of research activity, and 7th for quality according to Times Higher Education rankings. Eighty-four percent of research at Kings was deemed world-leading or internationally excellent (3* and 4*). The university is in the top seven UK universities for research earnings and has an overall annual income of more than ?684 million.
For further information, please visit the website.
<b>Forward-looking Statements </b>
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or Auris Medicals strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on managements current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials of Auris Medicals product candidates, the clinical utility of Auris Medicals product candidates, including the likelihood that the TACTT3 trial may not meet its endpoints, the timing or likelihood of regulatory filings and approvals, Auris Medicals intellectual property position and Auris Medicals financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medicals capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medicals Annual Report on Form 20-F and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
<b>Contact:</b> Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, firstname.lastname@example.org
<b>Media contact:</b> David Schull, Russo Partners, 1-858-717-2310, email@example.com
<img src="http://www.globenewswire.com/newsroom/ti?ndecode=MTUwIzY3MDI2MjM=" alt="" width="1" height="1"/>